What is the purpose of Amgen's additional $300 million investment in Puerto Rico, and how does it fit into the company's broader U.S. manufacturing strategy?

Amgen's additional $300 million investment is specifically aimed at expanding its biologics manufacturing facility in Juncos, Puerto Rico — a site that distributes medicines to more than 60 countries — thereby strengthening its U.S. manufacturing footprint. This commitment builds on Amgen's previously announced $650 million investment in Puerto Rico last year, which is expected to create 750 jobs, and aligns with its wider domestic investment strategy that includes $900 million in Ohio, $600 million for a science and innovation center in California, and over $1.5 billion in North Carolina.

How is Amgen's manufacturing expansion linked to U.S. trade policy under President Trump?

Amgen's expansion is directly tied to President Donald Trump's April executive order imposing up to 100% tariffs on imported branded pharmaceuticals unless manufacturers agree to government drug-pricing deals or commit to domestic production — prompting global drugmakers, including Amgen, to boost U.S.-based manufacturing capacity in response.

Amgen to invest additional $300 million to boost US manufacturing footprint

May 4, 2026

Amgen announced a $300 million investment to expand its Puerto Rico biologics manufacturing facility amid potential U.S. tariffs on imported medicines. This expands prior commitments totaling over $1.5 billion to boost domestic production capacity.

reuters

2026-05-04

Amgen to invest additional $300 million to boost US manufacturing footprint

Amgen to invest additional $300 million to boost US manufacturing footprint

FAQ